SAREUM HOLDINGS PLC

AGM Information • Dec 17, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1939X

Sareum Holdings PLC

17 December 2019

(AIM: SAR)

17 December 2019

Sareum Holdings plc

("Sareum" or the "Company")

Results of AGM

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting ("AGM") today and all resolutions were duly passed on a poll. Details of the proxy voting are shown in the table below.

In addition, the Board of Directors confirmed at the AGM that all executive and non-executive directors had entered into a salary deferral scheme, whereby 33% of directors' salaries are being deferred until further notice, as part of the Company's efforts to maximise its cash resources.

Ordinary resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive the Annual report and accounts for the Company	339,577,999	99.65	1,187,470	0.35	340,765,469	11.09%	2,191,331
2. Approve the Directors' Remuneration Report	327,161,863	95.45	15,603,606	4.55	342,765,469	11.16%	191,331
3. Re-elect Dr John Reader as a director	339,084,553	99.45	1,872,247	0.55	340,956,800	11.10%	2,000,000
4. Appoint Shipleys LLP as auditor	340,472,792	99.86	484,008	0.14	340,956,800	11.10%	2,000,000
5. Directors' authority to allot new shares	301,404,835	88.77	38,112,158	11.23	339,516,993	11.05%	3,439,807
Special Resolution
6. Disapplication of pre-emption rights	298,109,670	87.51	42,545,299	12.49	340,654,969	11.09%	2,301,831

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available on the Company's website (www.sareum.com)

This announcement contains inside information for the purposes of the market abuse regulation (EU No. 596/2014) ("MAR").

For further information, please contact: 

Sareum Holdings plc
Tim Mitchell	01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch	020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse	020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Mark Swallow / David Dible	020 7638 9571

Notes for editors:

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a $328.5m plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGCKODNNBDDQBD